A Phase 1, Single-arm, Open-label, Dose-escalation Study of AFP Specific T Cell Receptor Transduced T Cells Injection(HRYZ-T102)in Patients With AFP Positive Advanced Hepatocellular Carcinoma and Other Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.
100 项与 HRYZ-T102 相关的专利(医药)